NCT00094770View on ClinicalTrials.gov

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,172

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2007

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

sitagliptin (MK0431)

Sitagliptin 100 mg oral tablets of sitagliptin once daily.

DRUG

Comparator: glipizide

Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00094770 - An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) | Biotech Hunter | Biotech Hunter